Accelerate Diagnostics (NASDAQ: AXDX) and Dynatronics Corporation (NASDAQ:DYNT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Earnings & Valuation

This table compares Accelerate Diagnostics and Dynatronics Corporation’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Accelerate Diagnostics $1.29 million 859.17 -$61.92 million ($1.23) -17.32
Dynatronics Corporation $32.72 million 0.29 -$261,530.00 ($1.05) -2.43

Dynatronics Corporation has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Dynatronics Corporation, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Accelerate Diagnostics and Dynatronics Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Accelerate Diagnostics -5,062.48% -67.44% -63.75%
Dynatronics Corporation -7.24% -152.17% -14.67%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Accelerate Diagnostics and Dynatronics Corporation, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accelerate Diagnostics 0 0 2 0 3.00
Dynatronics Corporation 0 0 0 0 N/A

Accelerate Diagnostics currently has a consensus target price of $33.00, suggesting a potential upside of 54.93%. Given Accelerate Diagnostics’ higher possible upside, equities research analysts plainly believe Accelerate Diagnostics is more favorable than Dynatronics Corporation.

Institutional & Insider Ownership

38.5% of Accelerate Diagnostics shares are owned by institutional investors. Comparatively, 14.9% of Dynatronics Corporation shares are owned by institutional investors. 51.4% of Accelerate Diagnostics shares are owned by insiders. Comparatively, 63.9% of Dynatronics Corporation shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Accelerate Diagnostics has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. Comparatively, Dynatronics Corporation has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

About Dynatronics Corporation

Dynatronics Corporation is a manufacturer and distributor of physical medicine products. The Company’s products include a line of medical equipment for physical medicine applications, including therapy devices, medical supplies and soft goods, treatment tables and rehabilitation equipment. Its products are used by physical therapists, chiropractors, sports medicine practitioners, podiatrists, physicians and other physical medicine professionals. Its physical medicine products include therapeutic modalities, such as Dynatron Solaris, including electrotherapy and thermal therapy, and 25 Series, including electrotherapy and ultrasound; manufactured capital products, including traction systems and wood furniture; manufactured supplies, including cold packs, straps, wedges, bolsters and mats; distributed capital products, including hydrotherapy, weight training equipment and pilates, and distributed supplies, including clinical accessories, sports med and taping products, lotions and gels.

Receive News & Stock Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related stocks with our FREE daily email newsletter.